Tempus AI Trades Above the Targets in Its Own Headlines: 50% Growth, Half the Peer Multiple, and One Failing Grade

A stock that jumps 70% in a month earns headlines. One that hands back 13% of that move in a few sessions earns scrutiny. Tempus AI has done both: shares climbed about 70% in a month into late August — from roughly $41.55 on July 29 to about $70.69 on August 27 — and now trade near $63, down from a late-August close around $72.69. The detail that deserves attention sits at the bottom: the coverage generating the headlines, a Piper Sandler note, repeated a Hold rating and cut its target price from $58 to $56. The stock trades well above the analyst target in its own news.

That gap is not a contradiction. It's the whole story, once you line up the catalyst, the actuals, and the comparison set.

The surge was fueled by someone else's landmark

The sharpest single leg of the rally had little to do with a Tempus trial result. On August 19, Merck and Moderna reported that their individualized cancer vaccine plus Keytruda met both primary endpoints in the Phase 3 INTerpath-001 trial in resected melanoma, improving recurrence-free and distant-metastasis-free survival versus Keytruda alone.

For Tempus the effect is indirect but real: it validates the personalized-cancer-vaccine business this company is built to serve. Tempus's moat story is the one of the largest libraries of clinical and molecular data, plus its data-sequencing pipeline and its own personalized cancer vaccine collaboration with BioNTech. But a landmark for Merck and Moderna is a halo for Tempus — it puts no trial result and no milestone payment on Tempus's income statement. The pullback from the low $70s to the low $60s is the market cooling that halo, quickly.

Under the noise, a real inflection in the actuals

About three weeks before that readout, Tempus reported a Q2 that changed the earnings trajectory for the first time. Revenue of $382.5 million was up 22% year over year, slightly above consensus. More importantly, Q2 swung to a $5.6 million GAAP profit versus a $42.8 million loss a year earlier — the first GAAP-profitable quarter of its short public life — while the adjusted loss narrowed to $0.04 per share against a $0.13 consensus. Data licensing and modeling revenue grew 36%, and the company booked $200 million in new data-and-modeling deals, the raw material of the AI narrative.

But respect the caveats before you frame this as a turnaround. Adjusted earnings are still negative. First-half net loss was $120.3 million. And the top line is decelerating: Q1 grew 36% year over year, Q2 just 22%, partly because Tempus is now lapping the 2025 Ambry acquisition. The profit is one quarter, not a record.

Cheap is meaningless until you pick a comparison set

Here is where the valuation picture stops being a headline and becomes a judgment. Tempus trades at roughly 7.9 times trailing sales. Natera, its closest large-cap comparable in genomic diagnostics, trades at about 17 times; Guardant Health at about 18 times. Veracyte, the profitable one, sits at 6.2 times — but it grows only 17%.

Now add the growth column. Tempus's trailing-twelve-month revenue is up roughly 50%, versus about 38% for Natera and 43% for Guardant. The fastest grower in the AI diagnostics group trades at roughly half the sales multiple of its two biggest comparable companies, and its gross margin of about 64% lines up with theirs. That is the sector-relative discount the unadjusted share price hides.

There is a reason for the discount, and it is the one failing grade. Tempus's operating margin is about -20%, its trailing free cash flow is roughly -$273 million, and return on equity is deeply negative. It carries about $600 million in cash against roughly $1.9 billion in debt, with no earnings anchor to hang a P/E on. In absolute terms the stock is not cheap — 25 times book, no profit multiple to compute. The comparison set is what makes the story legible: the market prices these names on sales because none of the fast growers earns, and on that yardstick Tempus is the discount grower chasing the biggest market.

Why the targets lag the tape

That is why Piper Sandler's $56 and the broader street sit behind the current price. An analyst model anchored to near-term earnings and cash burn produces a number like $56: adjusted EPS is still negative even after Tempus's best quarter. The market is paying for something the model cannot book — compounded revenue, data-licensing bookings, and the option on a vaccine-adjacent future.

Piper is hardly alone in being behind the tape. Coverage is genuinely split: roughly 11 of 18 analysts carry Buy ratings, six Hold, one Sell, with average targets clustering near $58-64 — at or slightly below where the market trades. A price target under the market price in this situation is not a sell signal. It is a flag that the debate has moved from "what are current earnings worth" to "can optionality become earnings." AInvest's aggregate signal carries a Buy label, which is directionally consistent with the factor stack I run; the qualification is that the buy case rests on growth and momentum, not on reported profit.

The report card, and what to do with it

Pulling the five factors together: Growth grades A — about 50% trailing revenue growth, fastest in its comparison set, though the Q2 print shows the deceleration to watch. Valuation is mixed, roughly a C+ — weak in absolute terms with no P/E anchor, reasonable relative to peers at half of Natera's and Guardant's sales multiples. Profitability grades F — negative operating margin, negative free cash flow, and a thin balance-sheet safety buffer given the debt-to-cash gap. Momentum grades A — the stock sits above both its 50-day and 200-day averages, with a 20-day gain near 37% and an RSI around 56, strong without yet being overbought. Revisions grade B+ — beats, narrowing losses, and $200 million in new bookings.

That stack earns a buy, but only with a named portfolio role and size discipline. This is an aggressive-growth satellite for the barbell's growth end, not a core holding and not a substitute for durable cash-flow or dividend income. The two triggers that would change the call: if third-quarter revenue growth keeps decelerating instead of stabilizing, and if the Q2 GAAP profit proves to be a single-quarter event rather than a habit. On the technical side, a break back below the 50-day average near $55 would be the process telling you the re-rating has stalled.

The headline asked whether a Piper note moved the stock premarket. The better question is what the price means once you stop treating a static target as gospel. Right now the market is paying growth-and-optionality prices for a company whose profitability grade is the gap you must close — which is why you size the position like a satellite and watch the growth and margin columns like the runway they are.